We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+55.52%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$7.04B
AUM Growth
+$1.98B
Cap. Flow
+$444M
Cap. Flow %
6.3%
Top 10 Hldgs %
74.64%
Holding
54
New
9
Increased
21
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$143M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$114M
3
PMVP icon
PMV Pharmaceuticals
PMVP
+$68.1M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$58.6M
5
ALT icon
Altimmune
ALT
+$40M

Top Sells

Rank Stock Value
1
ALLO icon
Allogene Therapeutics
ALLO
+$48.3M
2
ZGNX
Zogenix, Inc.
ZGNX
+$33.7M
3
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$27.1M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$25.3M
5
TCDA
Tricida, Inc. Common Stock
TCDA
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 66.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
51
PTC Therapeutics
PTCT
$6.12B
– –
-324,750
Closed -$16.5M
RVMD icon
52
Revolution Medicines
RVMD
$44B
– –
-304,000
Closed -$9.6M
TCDA
53
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-600,000
Closed -$16.5M
BDSI
54
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-2,034,900
Closed -$8.87M
1 2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Avoro Capital Advisors's Q3 2020 Portfolio in Review

As of Q3 2020, Avoro Capital Advisors held 54 positions worth $7.04B, up 39% from $5.06B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Avoro Capital Advisors deployed $444M of net new capital in Q3 2020, opening 9 new positions and adding to 21 existing holdings. Its largest new stake was PMV Pharmaceuticals: 1,850,000 shares worth $57.6M.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 80% a quarter earlier.

On the sell side, the largest reduction was Zogenix, Inc., an estimated $33.7M trimmed.

  • Avoro Capital Advisors's largest Q3 2020 buy was PMV Pharmaceuticals: 1,850,000 shares worth $57.6M.
  • Avoro Capital Advisors added most to Arena Pharmaceuticals Inc in Q3 2020, an estimated $143M increase.
  • Avoro Capital Advisors's biggest Q3 2020 reduction was Zogenix, Inc., cutting an estimated $33.7M.
  • Avoro Capital Advisors fully exited Allogene Therapeutics in Q3 2020, selling an estimated $48.3M.
  • Avoro Capital Advisors's ten largest holdings make up 75% of its $7.04B portfolio in Q3 2020.
  • Avoro Capital Advisors opened 9 new positions and closed 8 in Q3 2020.
  • Avoro Capital Advisors's portfolio value rose 39% quarter-over-quarter to $7.04B.

Based on Avoro Capital Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.